Cell Therapy Lab Lighting Critical for Industrialization

📢 $SLBT is officially listed on the Nasdaq Global Market — trading starts today. Formerly known as SL BIO Ltd., SL Science Holding Limited (Nasdaq: SLBT) marks a pivotal step — not just as a capital markets milestone, but as a declaration of where scalable allogeneic cell therapy is headed next. SL Science's off-the-shelf cellular therapy platform addresses standardization, manufacturing capacity, and cost barriers — transforming cell therapy from a bespoke procedure into a scalable, reproducible, platform-based model. We believe the most transformative force in precision medicine is a system that scales — not a breakthrough that can't. 🌐 https://lnkd.in/eg56ruJT 📩 ir@slbtgroup.com #SLBT #SLScience #Nasdaq #Biotech #CellTherapy #OncologyInnovation

What if the future of medicine looks less like chemistry...and more like software engineering? In this fascinating Progress, Potential, And Possibilities episode, I sit down with Dr. Jacob Becraft, Ph.D. - Co-Founder & CEO of Strand Therapeutics, to explore the emerging world of programmable mRNA therapeutics, synthetic biology, RNA logic circuits, and next-generation cancer immunotherapy. Long before mRNA became a household term, Dr. Becraft and his colleagues at Massachusetts Institute of Technology were developing one of the world’s first synthetic biology programming languages for mRNA - technology designed to allow therapies to sense their environment, make decisions inside cells, and activate only in the correct biological context. We discuss: 🧬 Programmable medicine; 🧬 Self-amplifying RNA; 🧬 MicroRNA “logic gates”; 🧬 Tumor-selective IL-12 therapies; 🧬 In vivo CAR-T technology; 🧬 Biological software systems; 🧬 The future of synthetic biology; 🧬 Why medicines may soon behave like engineered systems rather than static drugs; We also dive into Strand’s groundbreaking programs STX-001, STX-003, and STX-005 - and what it could mean if therapies can one day dynamically respond to disease states inside the body. One of the most mind-expanding biotech conversations I’ve had in a long time. Watch now - https://lnkd.in/eyCPvKWA #SyntheticBiology #ProgrammableMedicine #mRNA #CancerImmunotherapy #Biotech #StrandTherapeutics #JacobBecraft #FutureOfMedicine #GeneTherapy #PrecisionMedicine Thermal Lindsey Narkchareon Kaustuva Das Elena Shintani Ron Weiss

Reduce experimental burden and accelerate cell therapy development with a fluid dynamics-guided approach to process optimization. Traditional approaches demand extensive experimentation to define robust operating spaces. By using mixing characterization, flow regime identification, and shear profiling to mechanistically link operating conditions to hydrodynamic behaviour, development teams can narrow the experimental space before biological testing begins. Join us for a webinar where Thomas Heathman, Gergana Atanasova, and Shaun Mansfield from Ori Biotech demonstrate how this approach supports Quality by Design (QbD) frameworks and accelerates process optimization for key steps including CAR-T activation and lentiviral transduction on the IRO® platform. ⏰ Tuesday June 24, 10:00 EDT / 15:00 BST 📍 Online Register here ➡️ https://lnkd.in/e-aEgXks

Finding hits is only the beginning. The real challenge is transforming them into validated, progressible starting points that can drive drug discovery forward. That’s why ZoBio is excited to launch our integrated #DEL hit discovery platform, bringing together protein production, quantitative biophysics, DEL screening, off-DNA validation, and X-ray crystallography in a truly connected workflow. Rather than stopping at hit identification, we deliver mechanistically understood, structurally validated hit matter designed for confident progression in challenging drug discovery programs. Built for novel and difficult-to-drug targets, this approach reduces uncertainty early and enables better-informed decisions from the very start. Download our DEL Capabilities Whitepaper to learn more! https://lnkd.in/eWvdKUeh #DELscreening #hitidentification #hitfinding

How can advanced therapies move closer to scalable delivery? This IBTV Roving Reporter interview features Nina Bauer, PhD MBA of FUJIFILM Cellular Dynamics, Inc sharing insights from Advanced Therapies London 2026 on manufacturing innovation, automation, and the future of cell therapy scale-up. Watch the full video for all the insights 👇 https://ow.ly/BGbk50Z53rh #CellTherapy #GeneTherapy #Biotech

Parse Biosciences and bit.bio Announce Landmark Alliance https://lnkd.in/gQJWB9UE SEATTLE–(BUSINESS WIRE)–Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced an alliance with bit.bio to create a comprehensive map of transcription factor-driven cell identity, encompassing both cell state and cell fate. This map will serve as the foundational blueprint for developing highly accurate, human-relevant models at scale. By precisely mimicking in vivo biological responses, these models will significantly advance pred Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

𝗛𝗼𝘄 𝗱𝗼 𝘆𝗼𝘂 𝗰𝗿𝗲𝗮𝘁𝗲 𝗮 𝘁𝗿𝘂𝗹𝘆 𝗰𝗹𝗼𝘀𝗲𝗱 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄 𝗳𝗼𝗿 𝗮𝗱𝗵𝗲𝗿𝗲𝗻𝘁 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴? In our latest application note, developed together with Thermo Fisher Scientific, we demonstrate a fully closed workflow for microcarrier-based MSC expansion, harvest, washing, and concentration by integrating the Osilaris™ bioreactor platform with the Rotea™ Cell Processing System. Key highlights: ✔ Closed end-to-end workflow ✔ Efficient microcarrier-based MSC expansion ✔ High cell viability after harvest and processing ✔ Preservation of MSC phenotype Interested in the data and workflow details? Check the comments section to download the full Appnote! #CellTherapy #MSC #CellManufacturing #ATMP #RegenerativeMedicine

$CGTX CEO, will join H.C. Wainwright's Dr. Ram Selvaraju for a virtual fireside chat during their Neuro Perspectives Expert Summit. The virtual fireside will be available on demand beginning at 7:00am ET on June 15th. Find a link to the live and archived presentation on the Cognition Therapeutics IR webpage: https://lnkd.in/evXgUhBG #HCWConference #InvestorConference #BiotechInvesting #DementiaWithLewyBodies #DLBPsychosis #DLB

Small vesicles. Big discoveries. 🧬 Bioseen is proud to announce its partnership with EXODUS BIO, bringing advanced exosome and extracellular vesicle (EV) isolation solutions to researchers across the GCC. 🔬 As EV research continues to drive innovation in biomarker discovery, liquid biopsy, and regenerative medicine, reliable and reproducible isolation technologies are becoming increasingly important. Together with EXODUS BIO, we look forward to supporting scientists with solutions designed to simplify workflows and accelerate research. #Bioseen #ExodusBio #Exosomes #ExtracellularVesicles #EVResearch #LifeSciences #Biotechnology

Meet BioArctic at #BIO2026 🧬 Petter Wereen, Senior Director Business Development at BioArctic, will be speaking on June 23 at BIO International Convention, joining the session on the future of neuroscience and CNS innovation. CNS disorders are among the most complex and urgent challenges in global healthcare. This session will highlight the latest advances in CNS research and development, with experts from biotech, pharma, and investment discussing breakthroughs and how technology is speeding the path from discovery to treatment. Looking forward to great discussions! 🔗Read more about the program -> https://lnkd.in/dFS-GDMr